


U.S.S.N. 18/487,841
Pending Claims

References


1. A compound of
Formula (I):



or a pharmaceutically acceptable salt thereof, wherein

R₁ is absent, or hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C1-C12 alkoxy, C1-C12 haloalkyl, C3-C20 cycloalkyl, C3-C20 heterocyclyl, aryl, or heteroaryl, any of which is optionally substituted with one or more of halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, aryl, or heteroaryl; R₂ and R₃ are independently hydrogen, deuterium, halogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C1-C12 alkoxy, C1-C12 haloalkyl, C3-C20 cycloalkyl, C3-C20 heterocyclyl, aryl, or heteroaryl, any of which is optionally substituted with one or more of halogen, C1-

From the application of interest 18/487,841, Claim 1:
A compound of Formula (I):



wherein

R₁ is absent, or hydrogen


R₂ and R₃ are independently hydrogen

R' and R'' are independently hydrogen, C1-C6 alkyl

each R_x is independently hydrogen

1. Int'l Pat. App. Pub. No. WO/2021/089873 "Method of synthesis"
(Published May 14, 2021)

From Claim 1: A method of synthesizing a compound of formula III, or a pharmaceutically acceptable salt thereof, comprising stage 1 and stage 2, wherein stage 1 comprises:



wherein each XH is independently selected from protium...

n is selected from 0, 1...

R₁ is independently selected from -R₃, -OR₃, -O(CO)R₃, -F, -Cl, -Br or -I...


R₂ and R₃ are independently selected from C1-C4alkyl.

R₂ and R₃ are independently selected from C1-C4alkyl.

2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)

C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, aryl, or heteroaryl; or R2 and R3 together with the carbon atom to which they are attached form a C3-C20 cycloalkyl, aryl, or heteroaryl, any of which is optionally substituted with one or more halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, aryl, or heteroaryl; R' and R'' are independently hydrogen, C1-C6 alkyl, deuterated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or R' and R'' together with the nitrogen atom to which they are attached form a C3-C12 heterocyclyl or heteroaryl; and each Rx is independently hydrogen, —OH, methyl, methoxy, C1-C3 alkyl, C1-C6 haloalkyl, deuterated C1-C3 alkyl, C1-C3 alkoxy, —C(=O)OH, —C(=O)NR2R3, or halogen; wherein the compound is not

From Claim 1: A compound of Formula (Ia):



wherein,

R1 and **R10** are independently selected from hydrogen, C1 -C6 alkyl...

R1 and **R10** are independently selected from hydrogen, C1 -C6 alkyl...

R8 is -CR'2-, wherein each R' is independently selected from hydrogen...


n is selected from 2...

R9 is selected from C2-C6 alkyl...


R2 is selected from hydrogen...

R4, R5, R6, and R7 are each independently selected from hydrogen...

R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl, A, J, Q, and X;




R13 and **R14** taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;



2. The compound of claim 1, wherein R' and R'' are independently a C1-C6 alkyl.



From the application of interest 18/487,841, Claim 1:
A compound of Formula (I):




wherein

R1 is absent, or hydrogen

R2 and R3 are independently hydrogen

	<p><i>R'</i> and <i>R''</i> are independently hydrogen, C1-C6 alkyl each <i>R_x</i> is independently hydrogen</p> <p>1. Int'l Pat. App. Pub. No. WO/2021/089873 "Method of synthesis" (Published May 14, 2021)</p> <p>From Claim 1: A method of synthesising a compound of formula III, or a pharmaceutically acceptable salt thereof, comprising stage 1 and stage 2, wherein stage 1 comprises:</p>  <p style="text-align: center;">III</p> <p>wherein each XH is independently selected from protium... n is selected from 0, 1... R1 is independently selected from -R3, -OR3, -O(CO)R3, -F, -Cl, -Br or -I... R2 and R3 are independently selected from C1-C4alkyl. R2 and R3 are independently selected from C1-C4alkyl.</p>
<p>3. The compound of claim 1, wherein each <i>R_x</i> is independently hydrogen, —OH, methyl, methoxy, or halogen.</p>	<p><i>From the application of interest 18/487,841, Claim 1:</i> <i>A compound of Formula (I):</i></p>  <p>wherein R1 is absent, or hydrogen R2 and R3 are independently hydrogen R' and R'' are independently hydrogen, C1-C6 alkyl each <i>R_x</i> is independently hydrogen</p> <p>1. Int'l Pat. App. Pub. No. WO/2021/089873 "Method of synthesis" (Published May 14, 2021)</p> <p>From Claim 1: A method of synthesising a compound of formula III, or a pharmaceutically acceptable salt thereof, comprising stage 1 and stage 2, wherein stage 1 comprises:</p>



wherein each XH is independently selected from protium...
n is selected from 0, 1...


R1 is independently selected from -R3, -OR3, -O(CO)R3, -F, -Cl, -Br or -I...

R2 and R3 are independently selected from C1-C4alkyl.

R2 and R3 are independently selected from C1-C4alkyl.

4. The compound of claim 1, wherein R1 is absent and R2 and R3 together with the carbon atom to which they are attached form a C3-C20 cycloalkyl, C3-C20 heterocyclyl, aryl, or heteroaryl, any of which is optionally substituted with one or more halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, aryl, or heteroaryl.

*From the application of interest 18/487,841, Claim 1:
A compound of Formula (I):*



wherein


R1 is absent, or hydrogen

R2 and R3 are independently hydrogen

R' and R'' are independently hydrogen, C1-C6 alkyl each Rx is independently hydrogen

2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)

From Claim 1: A compound of Formula (Ia):








wherein,




R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl...




R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl...




R8 is -CR'2-, wherein each R' is independently selected from hydrogen...

n is selected from 2...


	<p>R9 is selected from C2-C6 alkyl... R2 is selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl , A, J, Q, and X;</p>  <p>J is  ;</p> <p>R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;</p>
<p>5. The compound of claim 1, wherein (i) one of R2 or R3 is hydrogen, and the other of R2 or R3 is C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C3-C12 cycloalkyl; or (ii) R2 and R3 together with the carbon atom to which they are attached form a C3-C12 cycloalkyl that is optionally substituted with one or more halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, aryl, or heteroaryl.</p>	<p>2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)</p> <p>From Claim 1: A compound of Formula (Ia):</p>  <p>(Ia);</p> <p>wherein, R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R8 is -CR'2-, wherein each R' is independently selected from hydrogen... n is selected from 2... R9 is selected from C2-C6 alkyl... R2 is selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl , A, J, Q, and X;</p>  <p>J is  ;</p> <p>R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or</p>

	<p>unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;</p>
<p>6. The compound of claim 1, wherein the compound comprises at least one deuterium atom.</p>	<p>1. Int'l Pat. App. Pub. No. WO/2021/089873 "Method of synthesis" (Published May 14, 2021)</p> <p>From Claim 1: A method of synthesising a compound of formula III, or a pharmaceutically acceptable salt thereof, comprising stage 1 and stage 2, wherein stage 1 comprises:</p> <div style="text-align: center;">  <p>III</p> </div> <p>wherein each XH is independently selected from protium and deuterium n is selected from 0, 1... R1 is independently selected from -R3, -OR3, -O(CO)R3, -F, -Cl, -Br or -I... R2 and R3 are independently selected from C1-C4alkyl. R2 and R3 are independently selected from C1-C4alkyl.</p>
<p>7. The compound of claim 1, comprising having a structure according to Formula (Ib):</p> <div style="text-align: center;">  </div> <p>or a pharmaceutically acceptable salt thereof, wherein R1 is absent and R2 and R3 together with the carbon atom to which they are attached form a C3-C20 cycloalkyl, aryl, or heteroaryl, any of which is optionally substituted with one or</p>	<p>2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)</p> <p>From Claim 1: A compound of Formula (Ia):</p> <div style="text-align: center;">  <p>(Ia);</p> </div> <p>wherein, R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R8 is -CR'2-, wherein each R' is independently selected from hydrogen... n is selected from 2... R9 is selected from C2-C6 alkyl... R2 is selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl , A, J, Q, and X;</p>

<p>more of halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, aryl, or heteroaryl.</p>	 <p>J is  ;</p> <p>R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;</p>
<p>8. The compound of claim 1, selected from: 3-(2-(dimethylamino)ethyl)-1H-indol-4-yl furan-3-carboxylate; 3-(2-(dimethylamino)ethyl)-1H-indol-4-yl 2-fluorobenzoate; 3-(2-(dimethylamino)ethyl)-1H-indol-4-yl 3-fluorobenzoate; 3-(2-(dimethylamino)ethyl)-1H-indol-4-yl 4-fluorobenzoate; or 3-(2-(dimethylamino)ethyl)-1H-indol-4-yl thiophene-2-carboxylate, or a pharmaceutically acceptable salt thereof.</p>	
<p>9. A pharmaceutical composition, comprising the compound of claim 1 and a pharmaceutically acceptable carrier.</p>	<p>2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)</p> <p>From Claim 1: A compound of Formula (Ia):</p>  <p>(Ia);</p>

	<p>wherein, R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R8 is -CR'2-, wherein each R' is independently selected from hydrogen... n is selected from 2... R9 is selected from C2-C6 alkyl... R2 is selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen, C1 -C6 alkyl, A, J, Q, and X;</p>  <p>J is  ;</p> <p>R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;</p> <p>From [0179]: The compounds described herein may be formulated as a pharmaceutical composition. A pharmaceutical composition may comprise: (i) a modified indole alkaloid provided herein; and (ii) a pharmaceutically acceptable carrier, diluent, or excipient.</p>
<p>10. A method for treating one or more conditions that are responsive to serotonin receptor activation, comprising administering to a subject in need thereof an effective amount of the compound of claim 1.</p>	<p>2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)</p> <p>From Claim 1: A compound of Formula (Ia):</p>  <p>(Ia);</p> <p>wherein, R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R8 is -CR'2-, wherein each R' is independently selected from hydrogen... n is selected from 2... R9 is selected from C2-C6 alkyl... R2 is selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen...</p>

R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl , A, J, Q, and X;




R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;

From [0209]: Compositions described within this disclosure include modified indole alkaloids which have therapeutic uses for mental disorders including, but not limited to, depressive and anxiety disorders

11. A method for treating a neurological disease, comprising administering to a subject in need thereof an effective amount of the compound of claim 1.

2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)

From Claim 1: A compound of Formula (Ia):



wherein,

R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl...

R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl...

R8 is -CR'2-, wherein each R' is independently selected from hydrogen...


n is selected from 2...

R9 is selected from C2-C6 alkyl...



R2 is selected from hydrogen...

R4, R5, R6, and R7 are each independently selected from hydrogen...

R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl , A, J, Q, and X;




R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or

	<p>unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;</p> <p>From [0209]: Compositions described within this disclosure include modified indole alkaloids which have therapeutic uses for mental disorders including, but not limited to, depressive and anxiety disorders</p>
<p>12. The method of claim 11, wherein the neurological disease is a neurodegenerative disease, stupor and coma, dementia, seizure, sleep disorder, trauma, infection, neoplasm, neuro-ophthalmological condition, movement disorder, demyelinating disease, spinal cord disorder, disorder of peripheral nerves, muscle and neuromuscular junctions, psychiatric disorder, pain, or a disease associated with pain.</p>	<p>2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)</p> <p>From Claim 1: A compound of Formula (Ia):</p> <div style="text-align: center;">  <p>(Ia);</p> </div> <p>wherein, R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R8 is -CR'2-, wherein each R' is independently selected from hydrogen... n is selected from 2... R9 is selected from C2-C6 alkyl... R2 is selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen... R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl, A, J, Q, and X;</p> <div style="text-align: center;">  <p>J is</p> </div> <p>R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;</p> <p>From [0209]: Compositions described within this disclosure include modified indole alkaloids which have therapeutic uses for mental disorders including, but not limited to, depressive and anxiety disorders</p>
<p>13. The method according to claim 12, wherein the psychiatric</p>	<p>2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)</p>

disorder is: an anxiety disorder including acute stress disorder agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, or specific phobia; a childhood disorder including attention-deficit/hyperactivity disorder, conduct disorder, or oppositional defiant disorder; an eating disorder including anorexia nervosa or bulimia nervosa; a mood disorder including depression, bipolar disorder, cyclothymic disorder, dysthymic disorder, or major depressive disorder; a personality disorder including antisocial personality disorder, avoidant personality disorder, borderline personality disorder, dependent personality disorder, histrionic personality disorder, narcissistic personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder, schizoid personality disorder, or schizotypal personality disorder; a psychotic disorder including brief psychotic disorder,

From Claim 1: A compound of Formula (Ia):



wherein,

R1 and **R10** are independently selected from hydrogen, C1 -C6 alkyl...

R1 and **R10** are independently selected from hydrogen, C1 -C6 alkyl...

R8 is -CR'²-, wherein each R' is independently selected from hydrogen...


n is selected from 2...

R9 is selected from C2-C6 alkyl...

R2 is selected from hydrogen...


R4, R5, R6, and R7 are each independently selected from hydrogen...

R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl, A, J, Q, and X;



R13 and **R14** taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;

From [0209]: Compositions described within this disclosure include modified indole alkaloids which have therapeutic uses for mental disorders including, but not limited to, depressive and anxiety disorders

<p>delusional disorder, schizoaffective disorder, schizophreniform disorder, schizophrenia, or shared psychotic disorder; a substance-related disorder including alcohol dependence, amphetamine dependence, cannabis dependence, cocaine dependence, hallucinogen dependence, inhalant dependence, nicotine dependence, opioid dependence, phencyclidine dependence, or sedative dependence; an adjustment disorder, autism, delirium, dementia, multi-infarct dementia, a learning or memory disorder including amnesia or age-related memory loss; or Tourette's disorder.</p>	
<p>14. The method of claim 12, wherein the neurological disease is pain, or a disease associated with pain.</p>	<p>2. Int'l Pat. App. Pub. No. WO/2022/133314 "Modified indole alkaloids for therapeutic uses" (Published June 23, 2022)</p> <p>From Claim 1: A compound of Formula (Ia):</p>  <p style="text-align: center;">(Ia);</p> <p>wherein, R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R1 and R10 are independently selected from hydrogen, C1 -C6 alkyl... R8 is -CR'2-, wherein each R' is independently selected from hydrogen...</p>


n is selected from 2...

R9 is selected from C2-C6 alkyl...

R2 is selected from hydrogen...

R4, R5, R6, and R7 are each independently selected from hydrogen...

R4, R5, R6, and R7 are each independently selected from hydrogen, C1 - C6 alkyl, A, J, Q, and X;



R13 and R14 taken together with the atom to which they are attached to form a substituted or unsubstituted C3-C8cycloalkyl or substituted or unsubstituted 3- to 8-membered heterocycloalkyl having 1 or 2 heteroatoms each independently selected from N, O, and S;

From [0209]: Compositions described within this disclosure include modified indole alkaloids which have therapeutic uses for mental disorders including, but not limited to, depressive and anxiety disorders

From [0007]: The modified indole alkaloids discussed herein have therapeutic uses including, but not limited to, treatment of major depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, mania, psychosis, insomnia, hypersomnia, pain...



P.O. Box 1450
 Alexandria, VA 22313 - 1450
 www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/487,841	09/30/2024 05:22:51 PM Z ET	

Title of Invention

Application Information

APPLICATION TYPE	PATENT #
CONFIRMATION #	FILED BY Jeremy Rolquin
PATENT CENTER # 67383280	FILING DATE 10/16/2023
CUSTOMER # -	FIRST NAMED INVENTOR
CORRESPONDENCE ADDRESS -	AUTHORIZED BY -

Documents

TOTAL DOCUMENTS: 7

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
third-party-preissuance-submission.pdf	2	Third-Party Submission Under 37 CFR 1.290	46 KB
Concise-description-generated.pdf	2	Concise Description of Relevance	25 KB
Third-party-notification-request.pdf	1	Request for Notification of Non-compliant Third-Party Submission	13 KB
3PS Embedded.pdf	15	-	336 KB
3PS Embedded-3P.RELEVANCE.pdf	(1-15) 15	Concise Description of Relevance	338 KB
3PS Embedded-3P.RELEVANCE.pdf	(1-15) 15	Concise Description of Relevance	338 KB
WO2021089873A1 embedded.pdf	2	-	1389 KB

WO2021089873A1 embedded-FOR.pdf	(1-2)	2	Foreign Reference	1383 KB
WO2022133314A1 embedded.pdf		3	-	2313 KB
WO2022133314A1 embedded-FOR.pdf	(1-3)	3	Foreign Reference	2308 KB

Digest

DOCUMENT

MESSAGE DIGEST(SHA-512)

third-party-preissuance- submission.pdf	52CC7D8A6824B879B814BB97A655121E4E54768998855DDBF 96ED51995AC6F1257F9A95480F15552123F43828A57FB2B49C F2853ED1A0841776F5F693A1662B5
Concise-description- generated.pdf	8A7A57B960F487FD3B84A3FA346E8839C6F8FEEFD3F18E973 28CCD0F3D1D2382DD6E4C4E0BB90D5E53AAF099B933DA4E 80F6CA35BBF1F102EB609305B2420683
Third-party-notification- request.pdf	1C594406B4D628D98AEA11F0D32FD84479ADEAF35262DBEB B221C17934B30142BF82DF20EF3D0B55008D54035250293B39 DB95F8744AA64158AFA81DA3522840
3PS Embedded.pdf	EB30EA0894954FC8152D0D39BA770FA2E2A589BA6C1FD2440 E52194E094FA837F500E8D181C3472B3737AF8EE1D0F54BE9 777FF0182027AE388BE3774AF11B5E
3PS Embedded- 3P.RELEVANCE.pdf	9C84116A84D447B0EDCCEEC0BFD5B80D2DDBE1B7651E9178 A7E9A95A614CB75E524C1FC9C1AAB8FAE465D8D19AD2EEC 73ADCF507F4A91381837A9E41D73357E6D
3PS Embedded- 3P.RELEVANCE.pdf	CAA0C00B2E70C51C70B3461E9EC5CD5FB7C9DFED19CDBF D1D85886FD4A6C2954AC3571C1DB1E821CE66F600237E522F 1D7FE1EF5BA15266B5316FA7289E92B9D
WO2021089873A1 embedded.pdf	ABFD881C7EBA63CB30D53F0178B2ECC4E1D62969E789ACE2 9873694258996E03C1AF8402273B9EDF2CF0C4B6FB3DD2C73 04419FA0C31C2B617B02A5B64D60172
WO2021089873A1 embedded- FOR.pdf	22D10B7C1CFDB447C880C2BD37F292BB318F815E22A7ACC2 664AE8FE0E966D159FFACD44BF7AB9E1A306C9FC32D03E60 DD47F84ECE5F78D9B5EEEBA8242268AD
WO2022133314A1 embedded.pdf	5A73604B50544922B2FC9D4684A80BCA318ABD10510DFF90D 477006683BED3B3C61F3839E7E33508CDE5E63805968D1B52 08AF4DFD94F046C1CD74E31F641531
WO2022133314A1 embedded- FOR.pdf	9E61C0265540148981B9AC13D8278458C24AF4B63608A392B2 4E7FDE79568EC36D0E639642BDE2F8D03E59DD0B118BA9C3

799D35194F8AB2C4DD11F926A0CDE4

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.